Histogenics (HSGX) Tops Q2 EPS by 5c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/28/2026

1. ENPH
2. HOOD
3. BA
4. STX
5. NXPI
6. KIDS
7. V
8. CSGP
9. UPS
10. MANH

Go back to Histogenics (HSGX) Tops Q2 EPS by 5c

Histogenics Corporation Announces Second Quarter 2017 Financial and Operating Results

August 10, 2017 6:30 AM EDT

Completed Enrollment in NeoCart® Phase 3 Clinical Trial Top-line Data and Potential BLA Filing Expected in Third Quarter of 2018 Defined Regulatory Pathway with Japan Pharmaceuticals and Medical Devices Agency Market Research in U.S. and Japan Points to Potential Large Markets with Significant Unmet Need

WALTHAM, Mass., Aug. 10, 2017 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq: HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, announced its financial and operational results for the quarter ended June 30, 2017. 

We achieved a... More